Peter Georges
Division of Pediatric Infectious Diseases, Rhode Island Hospital, Brown Medical School, Providence, RI, USA.
Clin Infect Dis. 2006 Mar 1;42 Suppl 3:S138-40. doi: 10.1086/499593.
Less than 1 year after recommendations for the routine vaccination of infants with the newly licensed 7-valent polysaccharide-protein conjugate pneumococcal vaccine were issued in February 2000, shortages of the 7-valent polysaccharide-protein conjugate pneumococcal vaccine supply began to occur. A national shortage developed in 2001, involving both the public and private sectors, and it resulted in temporary recommendations to conserve vaccine supply for infants and young children at the highest risk for invasive disease. Multiple factors contributed to this vaccine shortage, including demand that exceeded the expectations of the manufacturer and the need for compliance with the Good Manufacturing Practice of the US Food and Drug Administration. Of the possible strategies that might have averted this shortage, establishment of a vaccine stockpile is the most likely solution. However, establishing a stockpile for a newly licensed vaccine, such as 7-valent polysaccharide-protein conjugate pneumococcal vaccine, presents unique challenges. Improved communication with physicians and parents regarding changes in vaccine schedules also will promote better adherence to recommended changes and conservation of limited vaccine supplies during a shortage.
2000年2月发布关于为婴儿常规接种新获许可的7价多糖-蛋白结合肺炎球菌疫苗的建议后不到1年，7价多糖-蛋白结合肺炎球菌疫苗供应便开始出现短缺。2001年出现了全国性短缺，涉及公共部门和私营部门，这导致临时建议为侵袭性疾病风险最高的婴幼儿保存疫苗供应。多种因素导致了此次疫苗短缺，包括需求超出制造商预期以及需要遵守美国食品药品监督管理局的《良好生产规范》。在可能避免此次短缺的策略中，建立疫苗储备是最有可能的解决方案。然而，为新获许可的疫苗（如7价多糖-蛋白结合肺炎球菌疫苗）建立储备存在独特挑战。就疫苗接种计划的变更与医生及家长加强沟通，也将促进在短缺期间更好地遵守建议的变更并节约有限的疫苗供应。
